WCN 2019 Discussions Point to Failures of Regulators to Make MS Therapies Available

WCN 2019 Discussions Point to Failures of Regulators to Make MS Therapies Available
0
(0)

There is a sizable gap between advancements in treatment for multiple sclerosis (MS) and their regulatory approval, which is a circumstance that necessitates increased  advocacy on a global scale.

This concern was a major topic of conversation recently at the XXIV World Congress of Neurology (WCN 2019) in Dubai, United Arab Emirates.

In recent years, especially in the past decade, there has been a surge in MS therapies that have undergone development, entered clinical trials, and  obtained regulatory approval.

“Few neurological conditions have seen advancements like that in the study of MS,” Alan Thompson, MD, said in a press release from the World Federation of Neurology (WFN), the organization that hosted WCN 2019. Thompson is chair of the Scientific Steering Committee of the International Progressive MS Alliance.

“MS has gone from being an untreatable condition to being a manageable disease which is an extraordinary story of achievement, but there is still a long way to go,” Thompson said. 

Despite recent progress, there often remains a disconnect between successful treatments in clinical trials, and those same treatments being approved by regulatory agencies. This is a concern on a global level because it invariably means that some people with MS won’t be able to access therapies that could be beneficial for them.

Indeed, there are regions where regulatory restrictions and/or delays prevent doctors from prescribing certain medications, which, according to the WFN, means that MS patients in these regions are more likely to experience disease progression or exacerbated disability.

“We have found that drugs do modify the disease,” said Bill Carroll, MD, president of the WFN and a neurologist at Sir Charles Gairdner Hospital in PerthWestern Australia.

But, Carroll noted, implementing these in practice often is hampered by “outdated clinical phenotypes” that are being found to poorly represent what actually happens in MS — although they are still being employed at the regulatory level.

According to Thompson, moving past these hurdles will require global initiatives to raise awareness and expand access to care. “International initiatives and awareness will help unlock greater funding for MS research and lead to more effective treatments,” he said.

“Our patients should be the number one priority,” Carroll said. “And it’s time for neurologists and MS physicians to adopt the approach that they should consider prescribing what is most appropriate for their patients today, despite what restrictions may have [been] put in place yesterday by regulators.”

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 1,053
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • ponesimod, NDA submission
  • ponesimod interview
  • Zeposia before EMA
  • clinical trial data

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Pin It on Pinterest

Share This